PMID- 27048303
OWN - NLM
STAT- MEDLINE
DCOM- 20171207
LR  - 20211204
IS  - 2157-1422 (Electronic)
IS  - 2157-1422 (Linking)
VI  - 6
IP  - 5
DP  - 2016 May 2
TI  - Inhibition of the Mechanistic Target of Rapamycin (mTOR)-Rapamycin and Beyond.
LID - 10.1101/cshperspect.a025924 [doi]
LID - a025924
AB  - Rapamycin is a Food and Drug Administration (FDA)-approved immunosuppressant and 
      anticancer agent discovered in the soil of Easter Island in the early 1970s. 
      Rapamycin is a potent and selective inhibitor of the mechanistic target of 
      rapamycin (mTOR) protein kinase, which acts as a central integrator of nutrient 
      signaling pathways. During the last decade, genetic and pharmaceutical inhibition 
      of mTOR pathway signaling has been found to promote longevity in yeast, worms, 
      flies, and mice. In this article, we will discuss the molecular biology 
      underlying the effects of rapamycin and its physiological effects, evidence for 
      rapamycin as an antiaging compound, mechanisms by which rapamycin may extend life 
      span, and the potential limitations of rapamycin as an antiaging molecule. 
      Finally, we will discuss possible strategies that may allow us to inhibit mTOR 
      signaling safely while minimizing side effects, and reap the health, social, and 
      economic benefits from slowing the aging process.
CI  - Copyright (c) 2016 Cold Spring Harbor Laboratory Press; all rights reserved.
FAU - Lamming, Dudley W
AU  - Lamming DW
AD  - Division of Endocrinology, Department of Medicine, University of 
      Wisconsin-Madison and William S. Middleton Memorial Veterans Hospital, Madison, 
      Wisconsin 53705.
LA  - eng
GR  - K99 AG041765/AG/NIA NIH HHS/United States
GR  - R00 AG041765/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20160502
PL  - United States
TA  - Cold Spring Harb Perspect Med
JT  - Cold Spring Harbor perspectives in medicine
JID - 101571139
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Immunosuppressive Agents)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Antibiotics, Antineoplastic/pharmacology
MH  - Humans
MH  - Immunosuppressive Agents/pharmacology
MH  - Longevity/*drug effects
MH  - Mice
MH  - *Signal Transduction
MH  - Sirolimus/*pharmacology
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC4852795
MID - NIHMS776038
EDAT- 2016/04/07 06:00
MHDA- 2017/12/08 06:00
PMCR- 2018/05/01
CRDT- 2016/04/07 06:00
PHST- 2016/04/07 06:00 [entrez]
PHST- 2016/04/07 06:00 [pubmed]
PHST- 2017/12/08 06:00 [medline]
PHST- 2018/05/01 00:00 [pmc-release]
AID - cshperspect.a025924 [pii]
AID - a025924 [pii]
AID - 10.1101/cshperspect.a025924 [doi]
PST - epublish
SO  - Cold Spring Harb Perspect Med. 2016 May 2;6(5):a025924. doi: 
      10.1101/cshperspect.a025924.